Videos

Cell therapies, which have made waves in the treatment of blood cancer, are showing potential for solid tumors.

Dr. Daniel J. Boffa discusses advancements in lung cancer care, including the role of minimally invasive surgical techniques and new systemic therapies.

CURE spoke with Dr. Marina Kremyanskaya about the treatment landscape for patients with polycythemia vera.

After more than 30 years since she was first diagnosed with a myeloproliferative neoplasm, Nona Baker is hopeful for the future thanks to current clinical trial landscape.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Panelists discuss how healthcare providers and patients should understand that talquetamab's unique side effects are temporary and resolve over time even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, attend all appointments, stay informed about myeloma research, and serve as active advocates who can communicate with healthcare teams when patients cannot.

Panelists discuss how patients beginning talquetamab should maintain a positive attitude, prepare thoroughly with educational materials, and understand that while initial side effects can be challenging, they are temporary and manageable with proper preparation and support.

Panelists discuss how patients can maintain nutrition during talquetamab treatment by focusing on texture and food presentation when taste is impaired, using high-calorie options, and remembering that taste changes and dry mouth are temporary side effects that improve over time.

Panelists discuss how specific talquetamab-related side effects like skin peeling, nail changes, and rashes can be effectively managed through targeted interventions including topical treatments, protective measures, and preventive strategies tailored to the drug's unique toxicity profile.

Panelists discuss how healthcare providers can develop comprehensive management protocols for talquetamab-related toxicities by consulting with specialists, gathering patient feedback, and creating detailed handouts that empower patients to proactively manage side effects before they begin treatment.

Panelists discuss how comprehensive patient education materials and manufacturer resources help patients prepare for and manage talquetamab side effects, with prior experience from CAR-T therapy providing valuable context for understanding potential complications like cytokine release syndrome.

Panelists discuss how healthcare providers must actively educate local oncologists, emergency departments, and community centers about bispecific antibody management as these therapies move from inpatient to outpatient settings, ensuring proper recognition and treatment of side effects like cytokine release syndrome.

Panelists discuss how successful talquetamab treatment requires coordinated care between inpatient and outpatient teams, comprehensive caregiver preparation including education materials and emergency contact information, and access to multidisciplinary healthcare providers as needed.

Panelists discuss how expectations for treatment outcomes can become more positive over time through experience with multiple therapies, staying informed about clinical trials and new treatments, and focusing on quality of life as a primary treatment goal alongside disease control.

Panelists discuss how caregivers can navigate the initial shock of a myeloma diagnosis by seeking reliable information from trusted medical websites, connecting with local support groups, and accessing resources from organizations such as the International Myeloma Foundation (IMF), Multiple Myeloma Research Foundation (MMRF), and patient advocacy groups.

Panelists discuss how Alan Plisskin's multiple myeloma diagnosis began with severe back and hip pain, progressed through life-threatening complications, including seizures and vocal cord paralysis, and revealed extensive lytic lesions throughout his body that required immediate intensive treatment.

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004.

Young adults with newly diagnosed cancer may feel overwhelmed, but open communication with doctors and support groups can help them feel less alone.

Dr. Joshua Sabai spoke with Dr. Chandler Park about the latest advances in kidney cancer, highlighting clinical trials that are shaping care for patients.

In honor of Lung Cancer Awareness Month, CURE spoke with Dr. Daniel J. Boffa about how the understanding of lung cancer is evolving beyond smoking.

Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care.

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.

After her own breast cancer treatment, Maureen advocated for legislation to make scalp cooling more accessible for patients seeking to preserve their hair.

Ten years after first being diagnosed with breast cancer, Cynthia Malaran said she still faces some side effects from treatment, but she has found strategies for coping.

Tracy Milgram-Posner sat down for an interview with CURE to discuss BRCAStrong and the impact she hopes to make for anyone with breast cancer.

Four-time non-Hodgkin lymphoma survivor Shell Rowe knows very well about the importance of finding the lighthearted side of an otherwise serious situation.

Experts highlight perioperative Padcev plus Keytruda in bladder cancer, showing potential practice-changing results from ESMO 2025 for patients.